168 related articles for article (PubMed ID: 14646172)
1. New fluoroprostaglandin F(2alpha) derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypotensive agents.
Nakajima T; Matsugi T; Goto W; Kageyama M; Mori N; Matsumura Y; Hara H
Biol Pharm Bull; 2003 Dec; 26(12):1691-5. PubMed ID: 14646172
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug.
Takagi Y; Nakajima T; Shimazaki A; Kageyama M; Matsugi T; Matsumura Y; Gabelt BT; Kaufman PL; Hara H
Exp Eye Res; 2004 Apr; 78(4):767-76. PubMed ID: 15037111
[TBL] [Abstract][Full Text] [Related]
3. Effects of prostaglandin F2alpha and latanoprost on phosphoinositide turnover, myosin light chain phosphorylation and contraction in cat iris sphincter.
Ansari HR; Davis AM; Kaddour-Djebbar I; Abdel-Latif AA
J Ocul Pharmacol Ther; 2003 Jun; 19(3):217-31. PubMed ID: 12828840
[TBL] [Abstract][Full Text] [Related]
4. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells.
Sharif NA; Kelly CR; Crider JY; Williams GW; Xu SX
J Ocul Pharmacol Ther; 2003 Dec; 19(6):501-15. PubMed ID: 14733708
[TBL] [Abstract][Full Text] [Related]
5. Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues.
Sharif NA; Kelly CR; Crider JY
Invest Ophthalmol Vis Sci; 2003 Feb; 44(2):715-21. PubMed ID: 12556403
[TBL] [Abstract][Full Text] [Related]
6. The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice.
Ota T; Aihara M; Narumiya S; Araie M
Invest Ophthalmol Vis Sci; 2005 Nov; 46(11):4159-63. PubMed ID: 16249494
[TBL] [Abstract][Full Text] [Related]
7. A comparative study of latanoprost (Xalatan) and isopropyl unoprostone (Rescula) in normal and glaucomatous monkey eyes.
Serle JB; Podos SM; Kitazawa Y; Wang RF
Jpn J Ophthalmol; 1998; 42(2):95-100. PubMed ID: 9587840
[TBL] [Abstract][Full Text] [Related]
8. Prostaglandin subtype-selective and non-selective IOP-lowering comparison in monkeys.
Gabelt BT; Hennes EA; Bendel MA; Constant CE; Okka M; Kaufman PL
J Ocul Pharmacol Ther; 2009 Feb; 25(1):1-8. PubMed ID: 19232013
[TBL] [Abstract][Full Text] [Related]
9. Microvascular effects of selective prostaglandin analogues in the eye with special reference to latanoprost and glaucoma treatment.
Stjernschantz J; Selén G; Astin M; Resul B
Prog Retin Eye Res; 2000 Jul; 19(4):459-96. PubMed ID: 10785618
[TBL] [Abstract][Full Text] [Related]
10. Responses of intraocular pressure and the pupil of feline eyes to prostaglandin EP1 and FP receptor agonists.
Bhattacherjee P; Williams BS; Paterson CA
Invest Ophthalmol Vis Sci; 1999 Nov; 40(12):3047-53. PubMed ID: 10549672
[TBL] [Abstract][Full Text] [Related]
11. Prostaglandin analogues and mouse intraocular pressure: effects of tafluprost, latanoprost, travoprost, and unoprostone, considering 24-hour variation.
Ota T; Murata H; Sugimoto E; Aihara M; Araie M
Invest Ophthalmol Vis Sci; 2005 Jun; 46(6):2006-11. PubMed ID: 15914616
[TBL] [Abstract][Full Text] [Related]
12. IOP-Lowering Effect of ONO-9054, A Novel Dual Agonist of Prostanoid EP3 and FP Receptors, in Monkeys.
Yamane S; Karakawa T; Nakayama S; Nagai K; Moriyuki K; Neki S; Suto F; Kambe T; Hirota Y; Kawabata K
Invest Ophthalmol Vis Sci; 2015 Apr; 56(4):2547-52. PubMed ID: 25788650
[TBL] [Abstract][Full Text] [Related]
13. Effects of prostaglandin F2alpha, latanoprost and carbachol on phosphoinositide turnover, MAP kinases, myosin light chain phosphorylation and contraction and functional existence and expression of FP receptors in bovine iris sphincter.
Ansari HR; Kaddour-Djebbar I; Abdel-Latif AA
Exp Eye Res; 2004 Feb; 78(2):285-96. PubMed ID: 14729360
[TBL] [Abstract][Full Text] [Related]
14. Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models.
Krauss AH; Impagnatiello F; Toris CB; Gale DC; Prasanna G; Borghi V; Chiroli V; Chong WK; Carreiro ST; Ongini E
Exp Eye Res; 2011 Sep; 93(3):250-5. PubMed ID: 21396362
[TBL] [Abstract][Full Text] [Related]
15. Agonist activity of bimatoprost, travoprost, latanoprost, unoprostone isopropyl ester and other prostaglandin analogs at the cloned human ciliary body FP prostaglandin receptor.
Sharif NA; Kelly CR; Crider JY
J Ocul Pharmacol Ther; 2002 Aug; 18(4):313-24. PubMed ID: 12222762
[TBL] [Abstract][Full Text] [Related]
16. Preclinical pharmacology of AL-12182, a new ocular hypotensive 11-oxa prostaglandin analog.
Sharif NA; McLaughlin MA; Kelly CR; Xu S; Crider JY; Williams GW; Parker JL
J Ocul Pharmacol Ther; 2006 Oct; 22(5):291-309. PubMed ID: 17076623
[TBL] [Abstract][Full Text] [Related]
17. A comparative, placebo-controlled study of prostanoid fluoroprostaglandin-receptor agonists tafluprost and latanoprost in healthy males.
Sutton A; Gilvarry A; Ropo A
J Ocul Pharmacol Ther; 2007 Aug; 23(4):359-65. PubMed ID: 17803434
[TBL] [Abstract][Full Text] [Related]
18. Prostaglandin derivates as ocular hypotensive agents.
Alm A
Prog Retin Eye Res; 1998 Jul; 17(3):291-312. PubMed ID: 9695796
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationships and receptor profiles of some ocular hypotensive prostanoids.
Resul B; Stjernschantz J; Selén G; Bito L
Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S47-52. PubMed ID: 9154276
[TBL] [Abstract][Full Text] [Related]
20. The effects of prostaglandin analogues on intracellular Ca2+ in ciliary arteries of wild-type and prostanoid receptor-deficient mice.
Abe S; Watabe H; Takaseki S; Aihara M; Yoshitomi T
J Ocul Pharmacol Ther; 2013 Feb; 29(1):55-60. PubMed ID: 23046436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
